Candida Bonelli

Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial

Carmine Pinto, Paolo Andrea Zucali, Maria Pagano et al. · The Lancet Oncology · 2021 · 103 citations

Medicine, Oncology, Pharmacology +12

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study

Francesco Iachetta, Candida Bonelli, Alessandra Romagnani et al. · British Journal of Cancer · 2019 · 34 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study

Roberta Minari, Giulia Mazzaschi, Paola Bordi et al. · Clinical Lung Cancer · 2020 · 30 citations

Medicine, Molecular Medicine, Oncology +16

Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study.

Maria Pagano, Giovanni Luca Ceresoli, Paolo Andrea Zucali et al. · Journal of Clinical Oncology · 2020 · 25 citations

Medicine, Oncology, Pharmacology +14

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study

Maria Pagano, Luca Giovanni Ceresoli, Paolo Andrea Zucali et al. · Cancers · 2020 · 24 citations · Full text

Medicine, Molecular Genetics, Oncology +17